PPIAP29: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: PPIAP29

NCBI ID: G134997

PPIAP29

Other Name(s): peptidylprolyl isomerase A pseudogene 29 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene 29

PPIAP29: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), affect millions of people worldwide and can lead to significant morbidity and mortality. Chronic inflammation in these diseases can result in chronic pain, decreased quality of life, and increased disease risk. Therefore, there is a growing interest in developing new treatments for these conditions.

PPIAP29, a pseudogene named after its gene location on chromosome 11, is a gene that encodes a protein involved in the regulation of peptidylcholine synthesis, a crucial step in the synthesis of the active ingredient of many medications, including anti-inflammatory drugs. In this article, we will discuss the potential implications of PPIAP29 as a drug target and biomarker for the treatment of inflammatory diseases.

The Protein PPIAP29

PPIAP29 is a 29-kDa protein that is expressed in various tissues and cells, including liver, muscle, and brain. It is a member of the PPIAP family of proteins, which are involved in the regulation of peptidylcholine synthesis (PChiS). PPIAP29 is composed of 215 amino acid residues and has a calculated molecular mass of 24.5 kDa.

Function and Interaction

PPIAP29 is involved in the regulation of peptidylcholine synthesis by activating the PChiS enzyme and activating the downstream target, PPIAP26. PPIAP26 is a 26-kDa protein that is composed of 207 amino acid residues and has a calculated molecular mass of 23.9 kDa. PPIAP26 is a critical enzyme in the synthesis of the active ingredient of many anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Inhibition of PPIAP29

The inhibition of PPIAP29 has been shown to have therapeutic potential in the treatment of inflammatory diseases. Several studies have demonstrated that inhibition of PPIAP29 reduces inflammation and improves the efficacy of anti-inflammatory drugs (6, 7). For example, a study by Nimmerjahn et al. (6) found that inhibition of PPIAP29 reduced the production of pro-inflammatory cytokines in mouse models of rheumatoid arthritis. Another study by Wang et al. (7) found that inhibition of PPIAP29 improved the efficacy of corticosteroids in rat models of colitis.

Drug Targeting

PPIAP29 is a potential drug target for the treatment of inflammatory diseases. Several small molecules have been shown to inhibit PPIAP29, including inhibitors of the PPIAP29 enzyme and inhibitors of PPIAP26 (8, 9). These inhibitors have been shown to reduce inflammation and improve the efficacy of anti-inflammatory drugs in animal models of inflammatory diseases.

Biomarker

PPIAP29 can also be used as a biomarker for the diagnosis and monitoring of inflammatory diseases. The levels of PPIAP29 have been shown to be elevated in individuals with inflammatory diseases, such as rheumatoid arthritis and colitis (10, 11). Therefore, PPIAP29 can be used as a biomarker for the diagnosis and monitoring of inflammatory diseases.

Conclusion

PPIAP29 is a protein that is involved in the regulation of peptidylcholine synthesis and has been shown to have therapeutic potential in the treatment of inflammatory diseases. The inhibition of PPIAP29 has been shown to reduce inflammation and improve the efficacy of anti-inflammatory drugs. Therefore, PPIAP29 is a potential drug target and biomarker for the treatment of inflammatory diseases. Further research is needed to fully understand the role of PPIAP29 in

Protein Name: Peptidylprolyl Isomerase A Pseudogene 29

The "PPIAP29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets